Drug name - Epanova

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(10 years from now)

CN104321055A ASTRAZENECA Dpa Composition Rich In Free Acid Form Of Omega -3 Polyunsaturated Fatty Acid
Aug, 2019

(3 years ago)

CN108524483A ASTRAZENECA Dpa-Rich Composition Of -3 Polyunsaturated Fatty Acid In Free Acid Form
Apr, 2021

(1 year, 5 months ago)

CN107050457A ASTRAZENECA Dpa Composition Rich In Free Acid Form Of Omega -3 Polyunsaturated Fatty Acid
May, 2021

(1 year, 4 months ago)

IN201406125P1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

IN344039B ASTRAZENECA Dpa Enriched Compositions Of Omega 3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563A4 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563B1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563A1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Dec, 2026

(4 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan, 2033

(10 years from now)

US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan, 2033

(10 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.